CD44 enhances tumor aggressiveness by promoting tumor cell plasticity

Oncotarget

Volumn 6, Issue 23, 2015, Pages 19634-19646

  Paulis, Yvette W J ^a,b   Huijbers, Elisabeth J M ^b   van der Schaft, Daisy W J ^a,d   Soetekouw, Patricia M M B ^a   Pauwels, Patrick ^c   Tjan Heijnen, Vivianne C G ^a   Griffioen, Arjan W ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

c Met; Cancer; CD44; Ewing sarcoma; Vasculogenic mimicry

Indexed keywords

CD44V6 ANTIGEN; HERMES ANTIGEN; HYALURONIC ACID; SCATTER FACTOR RECEPTOR; CD44 PROTEIN, HUMAN; ISOPROTEIN;

ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELLULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; EWING SARCOMA; EWING SARCOMA CELL LINE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL PLASTICITY; TUMOR VASCULARIZATION; VASCULOGENIC MIMICRY; BIOLOGICAL MIMICRY; BONE TUMOR; BREAST TUMOR; CELL MOTION; CELL TRANSDIFFERENTIATION; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; MCF-7 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHENOTYPE; PROCEDURES; PROTEIN ANALYSIS; RNA INTERFERENCE; VASCULARIZATION;

ANTIGENS, CD44; BIOLOGICAL MIMICRY; BONE NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL TRANSDIFFERENTIATION; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE REGULATORY NETWORKS; HUMANS; HYALURONIC ACID; MCF-7 CELLS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROTEIN INTERACTION MAPPING; PROTEIN ISOFORMS; RNA INTERFERENCE; SARCOMA, EWING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84939225247     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3839     Document Type: Article

References (47)

1. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, and Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. UNITED STATES; 1999;155:739-52.
2. Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Cohen MB, Lubaroff DM, and Hendrix MJ. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate. United States; 2002;50:189-201.
3. Passalidou E, Trivella M, Singh N, Ferguson M, Hu J, Cesario A, Granone P, Nicholson AG, Goldstraw P, Ratcliffe C, Tetlow M, Leigh I, Harris AL, Gatter KC, and Pezzella F. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer. Scotland; 2002;86:244-9.
4. Hendrix MJ, Seftor EA, Hess AR, and Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. England; 2003;3:411-21.
5. Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, and Hendrix MJ. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther. United States; 2002;1:661-4.
6. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, and Konishi F. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer. United States; 2002;99:821-8.
7. van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, Tran MG, Sciot R, Hauben E, Hogendoorn PC, Delattre O, Maxwell PH, Hendrix MJ, and Griffioen AW. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. United States; 2005;65:11520-8.
8. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, and Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta. Netherlands; 2010;1806:18-28.
9. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, and Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. England; 2010;468:829-33.
10. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, and De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. England; 2010;468:824-8.
11. Jürgens H, and Dirksen U. Ewing sarcoma treatment. Eur J Cancer. England; 2011;47 Suppl 3:S366-7.
12. Naor D, Sionov RV, and Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. UNITED STATES; 1997;71:241-319.
13. Ponta H, Sherman L, and Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. England; 2003;4:33-45.
14. Griffioen AW, Coenen MJ, Damen CA, Hellwig SM, van Weering DH, Vooys W, Blijham GH, and Groenewegen G. CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. Blood. UNITED STATES; 1997;90:1150-9.
15. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. England; 2004;4:528-39.
16. Lesley J, Hyman R, and Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol. UNITED STATES; 1993;54:271-335.
17. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H, and Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. UNITED STATES; 1991;65:13-24
18. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Sasaki I, and Matsuno S. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer. United States; 2001;91:67-75.
19. Griffioen AW, Horst E, Heider KH, Wielenga VJ, Adolf GR, Herrlich P, and Pals ST. Expression of CD44 splice variants during lymphocyte activation and tumor progression. Cell Adhes Commun. SWITZERLAND; 1994;2:195-200.
20. Kahara N, Ozaki T, Doi T, Nishida K, Kawai A, Shibahara M, and Inoue H. CD44 expression in soft tissue sarcomas. Virchows Arch. GERMANY; 2000;436:574-8.
21. Koopman G, Heider KH, Horst E, Adolf GR, van den Berg F, Ponta H, Herrlich P, and Pals ST. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med. UNITED STATES; 1993;177:897-904.
22. Marhaba R, and Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. Netherlands; 2004;35:211-31.
23. de los Toyos J, Jalkanen S, and Butcher EC. Flow cytometric analysis of the Hermes homing-associated antigen on human lymphocyte subsets. Blood. UNITED STATES; 1989;74:751-60.
24. Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Héroult M, Augustin HG, Ponta H, and Orian-Rousseau V. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood. United States; 2009;114:5236-44.
25. Singleton PA, Salgia R, Moreno-Vinasco L, Moitra J, Sammani S, Mirzapoiazova T, and Garcia JG. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem. United States; 2007;282:30643-57.
26. Corso S, Comoglio PM, and Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med. England; 2005;11(6):284-92.
27. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, and Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. United States; 2002;16:3074-86.
28. van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L, David G, Hartmann G, Gherardi E, and Pals ST. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem. UNITED STATES; 1999;274:6499-506.
29. van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW, and Hendrix MJ. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst. United States; 2004;96:1473-7.
30. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, and Hendrix MJ. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol. United States; 2012;181:1115-25.
31. Carmeliet P, and Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. England; 2011;473:298-307.
32. van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, and Griffioen AW. The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy. Pharmacol Rev. 2015;67:441-461.
33. Qu B, Guo L, Ma J, and Lv Y. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system. Med Hypotheses. United States; 2010;74:360-1.
34. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, and Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. United States; 2008;133:704-15.
35. Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV, Truong KD, and Phan NK. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med. England; 2011;9:209.
36. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, and Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. England; 2008;98:756-65.
37. Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, and Manjili MH. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol. United States; 2012;43:364-73.
38. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, and De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. England; 2010;468:824-8.
39. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, and Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. United States; 2009;8:158-66.
40. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, Strizzi L, and Hendrix MJ. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res. United States; 2010;70:10340-50.
41. Ishida T. Immunohistochemical expression of the CD44 variant 6 in colorectal adenocarcinoma. Surg Today. JAPAN; 2000;30:28-32.
42. Lyzak JS, Yaremko ML, Recant W, Baunoch DA, and Joseph L. Role of CD44 in nonpalpable T1a and T1b breast cancer. Hum Pathol. UNITED STATES; 1997;28:772-8.
43. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, König H, Weg-Remers S, and Ponta H. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci. UNITED STATES; 2000;910:106-18; discussion 118-20.
44. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A, and Simmons DL. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res. UNITED STATES; 1994;54:4539-46.
45. Fan YL, Zheng M, Tang YL, and Liang XH. A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett. 2013;6:1174-1180.
46. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, and Hendrix MJ. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res. United States; 2012;18:2726-32.
47. Paulussen M, Ahrens S, Braun-Munzinger G, Craft AW, Dockhorn-Dworniczak B, Dörffel W, Dunst J, Fröhlich B, Göbel U, Häussler M, Klingebiel T, Koscielniak E, Mittler U, Rübe C, Winkelmann W, Voûte PA, Zoubek A, and Jürgens H. [EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study)-- preliminary results]. Klin Padiatr. GERMANY; 1999;211:276-83.